期刊
CANCER
卷 124, 期 19, 页码 3849-3855出版社
WILEY
DOI: 10.1002/cncr.31663
关键词
accelerated phase; BCR-ABL; blast phase; bone marrow biopsy; chronic myeloid leukemia
类别
资金
- Leukemia Department of The University of Texas MD Anderson Cancer Center [CA100632]
- Leukemia Specialized Program of Research Excellence Pathology Core
- MD Anderson cancer support grant (National Cancer Institute) [P30 CA016672]
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
BACKGROUND: The diagnosis of chronic myeloid leukemia (CML) is based on characteristic clinical and laboratory findings and the presence of BCR/ABL1 in the blood and/or bone marrow (BM). The utility of BM core biopsy in the workup of patients with CML has been questioned. METHODS: The potential added value of BM biopsy versus aspiration in the workup of a single-institution series of 508 patients with CML at their initial presentation was systematically assessed. BM biopsy was considered essential when it was needed to establish the disease phase, often because blast counts derived from aspirate smears were misleading because the biopsy specimen was more representative of the disease. BM biopsy was considered helpful if it was needed for other nonessential reasons. RESULTS: In 127 patients (25%), BM biopsy was either essential (109 patients) or helpful (18 patients). Patients with accelerated-phase (AP) or blast-phase (BP) disease often required a biopsy related to essential reasons. High-grade myelofibrosis (MF) was more frequent in patients with AP/BP disease than patients with chronic-phase disease (P = .0005), and the identification of BP disease required a BM biopsy assessment in 75% of the patients (P = .001). A follow-up BM evaluation more often yielded inadequate aspirates in patients with inadequate BM aspirates at the time of their initial diagnosis. CONCLUSIONS: BM core biopsy remains valuable in the workup of 25% of patients with CML because it facilitates identification of the disease phase or MF. The initial grade of MF is associated with the disease stage and outcome after therapy. BM biopsy is, therefore, indicated for patients with CML who have AP/BP disease or other findings suggestive of progressive disease. Bone marrow biopsy is valuable in the workup of approximately 25% of patients with chronic myeloid leukemia because it facilitates identification of the disease phase and myelofibrosis. Biopsy is indicated in patients with findings suggestive of progressive disease, and bone marrow myelofibrosis, when present, is associated with the disease stage and molecular outcome after therapy. (C) 2018 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据